Development and validation of a nomogram for urothelial cancer in patients with chronic kidney disease

Che-Yi Chou1,2,3, Kuo-Hsiung Shu4, Hung-Chun Chen5, Ming-Chang Wang6, Chia-Chu Chang7, Bang-Gee Hsu8, Tzen-Wen Chen9, Chien-Lung Chen10 & Chiu-Ching Huang11

Urothelial cancer (UC) is a common kidney cancer in Taiwan and patients with chronic kidney disease (CKD) are more at risk for UC than the general population. The diagnostic value of urine analysis and urine cytology is limited, especially in CKD patients. The aim of the study is to develop a nomogram to predict the risk of UC in CKD patients. We enrolled 169 UC patients and 1383 CKD patients from 9 hospitals in Taiwan between 2012 and 2015. CA125, HE4, clinical characteristics, and medical history were analyzed using multivariable logistic regression for its association with UC. A nomogram was developed to predict the risk of UC and was validated using Bootstrap. CA125 was associated with UC in CKD patients (OR: 5.91, 95% CI: 3.24–10.77) but HE4 was not (OR: 1.29, 95% CI: 0.67–2.35). A nomogram based on patients' age, estimated glomerular filtration rate, CA125 (log transformed), smoking, exposure of environmental toxin, use of nonsteroid anti-inflammatory drugs, and use of traditional Chinese medicine was conducted. The AUC of the nomogram was 0.90 (95% CI: 0.86–0.92, \( p < 0.01 \)). Serum CA125 may identify UC patients from CKD patients but has limited diagnostic value due to low sensitivity. The diagnostic value of serum CA125 level can be improved by the combination with clinical characteristics including age, renal function, and medical history.

Urothelial carcinoma (UC) is common cancer in chronic kidney disease (CKD) patients\(^1\). The incidence of UC in Taiwan is higher than that of other parts of the world with an unusually high incidence of 50 per 100,000 person-years\(^2,3\). The development of UC can be associated with multiple factors such as smoking\(^4\), drinking groundwater that contains heavy metals\(^5\), exposures to environmental toxins such as dye\(^6\) or organic solvent\(^7\), and Chinese herbs that contain aristolochic acid (AA). Aristolochic acid can be the cause of both CKD and UC\(^8,9\). Epigenomic factors such as CKD\(^10\) and exposure to heavy metals\(^11\), aristolochic acid\(^12\), other environmental carcinogen exposures\(^1\) are strongly associated with UC. Urinalysis and urine cytology are the major screening tools in a clinical setting; however, the diagnostic performance of these tests are poor\(^16,17\). Serum markers such as Carcinoma antigen (CA125)\(^18,19\) and human epididymis protein 4 (HE4)\(^20\) are potential serum markers for the diagnosis of UC. The serum CA125 and HE4 can be elevated in CKD patients because the removal of these serum proteins is decreased with the decline of renal function\(^21,22\). The diagnostic value of CA125 and HE4 for UC in CKD patients is unclear. We aimed to develop a nomogram using serum biomarkers (CA125 and HE4), and clinical variables (such as age, gender, estimated glomerular filtration rate (eGFR), medical history for early detection of UC in CKD patients. As the medical history such as exposure to herbs and groundwater that contains

---

1Division of Nephrology and Kidney Institute, China Medical University and Hospitals, Taichung, Taiwan. 2Division of Nephrology, Asia University Hospital, Taichung, Taiwan. 3Department of Post-baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan. 4Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan. 5Division of Nephrology, Kaohsiung Medical University, Kaohsiung, Taiwan. 6Division of Nephrology, Cheng Kung University Hospital, Tainan, Taiwan. 7Division of Nephrology, Changhua Christian Hospital, Changhua, Taiwan. 8Division of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan. 9Division of Nephrology, Taipei Medical University, Taipei, Taiwan. 10Division of Nephrology, Landseed Hospital, Zhongli, Taiwan. 11Division of Nephrology and Kidney Institute, Department of Internal Medicine, China Medical University and Hospital, Taichung, Taiwan. Correspondence and requests for materials should be addressed to C.-C.H. (email: cch@mail.cmuh.org.tw)
heavy metals may be specific to endemic regions, the application of the nomogram may be limited to the endemic regions.

Methods

Study population and patient recruitment. This ongoing prospective, multi-center study of urothelial cancer (UC) was initiated by Taiwan Urothelial Cancer Consortium (TUCC) aiming to investigate the risk factors of UC with multiple risk domains (genes and environments). CKD patients without UC were recruited as a control group. The TUCC was coordinated by the Kidney Institute of China Medical University Hospital (Taichung, Taiwan) and the study was proposed to nephrology and urology divisions of the other nine hospitals. These hospitals had a diverse health care level from tertiary settings to local hospitals, agreed to participate in this study, which started the patient recruitment since July 2013. The consortium affiliated centers distributed throughout the country; four were in Northern Taiwan, 3 in Central Taiwan, 2 in Southern Taiwan, and 1 in Eastern Taiwan.

UC patients older than 20 years were identified consecutively in the urology department of each hospital and defined as adult patients with new or recurrent UC. All UC cases were verified by surgical and pathological reports. Control subjects, CKD patients with no known history of malignancy, were consecutively selected from the nephrology center of each hospital. After receiving detailed explanations of the study, each of the UC cases and controls provided written informed consent for the questionnaire interview and collection of blood and urine samples.

Ethics statement. The recruitment and follow-up protocols complied with the Declaration of Helsinki and were approved by the institutional review board of China Medical University Hospital (CMUH 102-REC2-043) and other nine hospitals.

Data collection. From July 2013 to December 2015, 1715 patients were enrolled and 163 patients with past UC who had no evidence of recurrence were excluded from the analysis (Fig. 1). All blood and urine were collected at enrollment. For UC patients, blood and urine samples were collected before surgical interventions.

Biomedical measurements. CA125 and HE4 were measured at the diagnosis of UC in the UC patients and at the enrollment in the CKD patients. The measurements of CA125 and HE4 were performed in a central laboratory using an electrochemiluminescence immunoassay on Cobas e411 Elecsys 2010 (Roche Diagnostics GmbH, Germany). Body mass index (BMI), serum blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR using CKD-EPI formula), serum uric acid, and serum albumin were measured.

Environmental exposures. Smoking was defined as a history of smoking >2 pack-years and/or smoking in the last year. Alcohol consumption was defined as ≥1 alcoholic drink per month. Groundwater use was defined as patients who reported a history of using groundwater as a source of drinking water for more than 6 months. Exposure to dye was defined as occupational exposure to dye for more than 6 months. Nonsteroid Anti-inflammatory Drugs (NSAIDs) use was defined as ingestion of NSAIDs more than four times per week. Use of traditional Chinese medicine (TCM) was defined as patients who had taken Chinese herbal remedies more than three times per year.

Statistical Analysis. Data are reported as the mean ± standard deviation, median (interquartile range, IRQ), or frequency (percentage), as appropriate. All continuous variables were tested for normality using the skewness
and kurtosis test. Data were analyzed using the t-test for normally distributed variables, the Mann-Whitney U test for non-normalized variables, or the chi-squared test for categorical variables. The diagnostic value of CA125 and HE4 for UC was analyzed using receiver operating characteristic (ROC) analysis and the area under the ROC curve (AUC) was calculated. The cut-off of CA125 was 35 U/ml and the cutoff of HE4 was 150 pmol/L for the diagnosis of ovarian cancer. The optimal cutoff of CA125 and HE4 for the diagnosis of UC may be higher because CKD patients were enrolled as controls in this study. The optimal cutoff for the diagnosis of UC was determined based on the results of ROC analysis. Possible risk factors of UC were analyzed using univariable logistic regression, followed by multivariable logistic regression. Odds ratios (ORs) and 95% confidence intervals (CIs) of OR were calculated. The factors associated with UC in multivariable logistic regression were used to generate a nomogram for UC. All analyses were performed using Stata (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.). The nomogram was developed using nomolog program for Stata and the nomogram was validated using rms packages of R software with bootstrap.

Results

Patient characteristics. From 2013 to 2015, 1715 patients were enrolled and 163 patients with past UC who had no evidence of recurrence were excluded from the analysis (Fig. 1). For control patients, blood and urine were collected at enrollment. For UC patients, blood and urine samples were collected before surgical interventions. One hundred and sixty-nine UC patients and 1383 CKD patients were analyzed in this study (Fig. 1 and Table 1). UC patients (mean age: 66 ± 11 years) were older than CKD patients (57 ± 13 years, p < 0.01). The BMI of UC patients was lower than that of CKD patients (p < 0.01). The CA125 (median: 18.7 U/ml, IRQ: 9.9–88.7 U/ml) of UC patients was significantly higher than that of CKD patients (median: 11.7, IRQ: 7.5–17.9, p < 0.01, Mann-Whitney U test). The HE4 was not different between UC and CKD patients. The eGFR of CKD patients was significantly lower than that of UC patients (p < 0.01). The proportion of patients with smoking (p < 0.01), use of NSAIDs (p < 0.01), with history of groundwater use (p = 0.01), exposure to toxins (p < 0.01), and use of TCM (p < 0.01) were significantly higher in UC patients than in CKD patients.

Development and validation of UC nomogram. The AUC of CA125 was 0.60 (95% CI: 0.55–0.65, p < 0.01) and the AUC of HE4 was 0.52 (95% CI: 0.47–0.57, p = 0.43) for the diagnosis of UC. CA125 was significantly higher in patients with UC but not HE4. The sensitivity and specificity of CA125 with a cutoff of 30 U/ml was 32.5% and 96.3%. CA125, HE4, age, BMI, eGFR, smoking, NSAIDs, toxins, groundwater, and TCM were associated with UC in univariable logistic regression (Table 2) and were further analyzed using multivariable logistic regression. Age, eGFR, CA125, NSAIDs, toxins, smoking, and TCM were independently associated with UC. The OR was 1.09 (95% CI: 1.06–1.11, p < 0.01) for every one additional year, 1.03 (95% CI: 1.02–1.04, p < 0.01) per ml/min/1.73 m² of eGFR, 3.03 (95% CI: 2.30–3.98) per log unit of CA125, 2.61 (95% CI: 1.37–4.97, p < 0.01) for smoking, 7.57 (95% CI: 3.81–15.03, p < 0.01) for NSAIDs, 3.33 (95% CI: 1.89–5.89, p < 0.01) for toxins, 8.25 (95% CI: 4.74–14.30, p < 0.01) for TCM. Age, eGFR, CA125, smoking, NSAIDs, toxins, and TCM were included in the nomogram Fig. 2. The sensitivity and specificity of the nomogram was 86.8% and 97.8%. The AUC of the nomogram was 0.91 and the goodness-of-fit index was 0.66. The nomogram was further internal validated using bootstrapping. As shown in Fig. 3, the X-axis is the predicted UC probability estimated by the nomogram and the Y-axis is the actual rates of UC. The solid line represents the ideal reference line that predicted UC corresponds to the actual outcome, and the dashed line represents the ideal estimation. The actual UC probability

| Characteristics | UC N = 169 | CKD N = 1383 | P |
|-----------------|------------|--------------|---|
| Age (year)      | 67         | 57           | <0.01|
| Male gender n%  | 109        | 800          | 0.85|
| BMI (kg/m²)     | 24.1       | 24.9         | 0.05|
| CA125 (U/ml)    | 18.7       | 11.2         | <0.01|
| HE4 (pmol/L)    | 178.5      | 136.6        | 0.43|
| BUN (mg/dl)     | 27         | 34           | <0.01|
| Creatinine (mg/dl) | 2.6     | 2.8          | 0.40|
| eGFR (ml/min/1.73 m²) | 51     | 44           | <0.01|
| Uric acid (mg/dl) | 6.6      | 6.5          | 0.63|
| Albumin (mg/dl) | 3.9        | 4.0          | 0.92|
| Smoking (n/%)   | 34         | 105          | <0.01|
| Alcohol (n/%)   | 20         | 126          | 0.40|
| NSAIDs          | 37         | 44           | <0.01|
| Groundwater (n%)| 13         | 53           | 0.01|
| Toxins (n/%)    | 61         | 102          | <0.01|
| TCM (n/%)       | 65         | 86           | <0.01|

Table 1. Clinical Characteristics of patients. BMI: body mass index, HE4: human epididymis protein 4, BUN: blood urea nitrogen, eGFR: estimated glomerular filtration rate using CKD-EPI formula, NSAIDs: Nonsteroid Anti-inflammatory Drugs, Toxins: exposure to dye, paint, or organic solvent, TCM: traditional Chinese medicine.
corresponded closely to the prediction of the nomogram. The calibration plot showed a good agreement between the prediction by nomogram and actual observation.

**Discussion**

This is the first study to develop a UC nomogram using commonly available tumor marker and clinical characteristics to identify UC in CKD patients who had a high risk of developing UC. We investigated the individual accuracy of CA125 or HE4 to predict UC in CKD patients. CA125 can identify UC patients from CKD patients with a higher cutoff (50 U/ml) but HE4 cannot. The log transformation of CA125 and HE4 were used in logistic regression because CA125 and HE4 were not normally distributed (Table 2). To minimize the measurement bias, all measurements of CA125 and HE4 were performed in a central laboratory. Other confounders of UC may have limited effect of the diagnostic value of CA125 because the ORs of CA125 were similar in Model 2 (including eGFR) and Model 3 (including medical history). The low sensitivity (32.5%) of CA125 for the diagnosis of UC can be further improved by the combination of medical history including patients' age, eGFR, and environmental carcinogen exposures. The medical history that is important for the diagnosis of UC includes a history of smoking, exposure to environmental toxins (dye, paint, and organic solvent), use of NSAIDs and use of TCM. The nomogram based on these risk factors revealed a good accuracy for the diagnosis of UC. The nomogram was further internal validated with bootstrapping technique. We are currently carrying out a prospective study to validate the usefulness of the nomogram in CKD patients.

The mean age of UC patients in this study is similar to the age of UC patients reported in previous studies. All UC patients were, in fact, CKD patients by the definition of CKD because they had pathologic abnormalities...

| Risk factors | Univariable | Multivariable |
|--------------|-------------|--------------|
|              | OR 95% CI   | OR 95% CI    |
| Age          | 1.07 1.05-1.09 | 1.09 1.06-1.11 |
| BMI          | 0.96 0.91-1.00 | 0.99 0.93-1.05 |
| eGFR         | 1.00 1.00-1.01 | 1.03 1.02-1.04 |
| CA125 (log)  | 2.46 2.08-2.92 | 3.03 2.30-3.98 |
| HE4 (log)    | 1.39 1.00-1.95 | 1.44 0.70-2.97 |
| Smoking      | 3.07 2.00-4.69 | 2.61 1.37-4.97 |
| NSAIDs       | 8.53 5.31-13.68 | 7.57 3.81-15.03 |
| Toxins       | 7.09 4.88-10.30 | 3.33 1.89-5.89 |
| Groundwater  | 2.09 1.12-3.92 | 0.84 0.31-2.29 |
| TCM          | 9.42 6.45-13.77 | 8.25 4.76-14.30 |

Table 2. Odds ratios (ORs) of possible risk factors for urothelial cancer. HE4: human epididymis protein 4, BMI: body mass index, eGFR: estimated glomerular filtration rate using CKD-EPI formula, NSAIDs: Nonsteroid Anti-inflammatory Drugs, Toxins: exposure to dye, paint, or organic solvent, TCM: use of traditional Chinese medicine.
in their urinary tracts; particularly if they received unilateral nephrectomy for upper urinary tract UC. However, this fact is often overlooked by urologists. UC patients were rarely referred to a nephrologist for regular follow up of renal function after surgery, as CKD patients did in clinical practice. Cancer risk in patients on dialysis had been extensively studied but little is known about the risk of dialysis in UC patients. After unilateral or bilateral nephrectomy, UC patients may reach advanced CKD stage and become dialysis dependent later on. This possibility reminds us to pay more attention to the follow up of renal function and care for CKD in UC patients after surgery.

Patients with a history of smoking are associated with UC and this fact is well supported by previous studies. An occupational exposure to dye, paint, or organic solvent is associated with UC and this is also well known from previous studies. The most striking finding in this study is patients who ever used TCM have a much higher probability of developing UC (OR: 8.25). Traditional Chinese medicines may contain aristolochic acid (AA) and/or heavy metals. Aristolochic acid is known as an important risk factor for developing UC and CKD but it is difficult to identify a history of AA exposure directly by questionnaire alone. We can only use history of TCM prescription as a surrogate indicator, and 38.5% of UC patients vs. 6.2% of control patients (p < 0.01) reported a history of receiving TCM prescription. This percentage can be under-estimated because of the short memory span in elderly patients. The best evidence of exposure to AA containing herbs would be to identify AA-DNA adducts in the urine. Using mass spectrometry, we tried to identify AA-DNA adducts in the urine as a surrogate marker for exposure to AA containing TCM, but none of the urine samples of UC patients had detectable AA-DNA adducts. Although AA containing TCM had been banned for importation to Taiwan since 2003, nevertheless, it is known that once exposed to AA, the carcinogenic effect may last for 30 years or longer.

There are some limitations to this study. First, we targeted CKD patients who are at high risk of UC and the risk of UC is increased in patients with lower renal function. However, the eGFR was positively associated with UC probability because most of the UC patients had a better renal function at the diagnosis of UC than those with CKD. The score of eGFR may be different when applying the nomogram in the general population. Second, a causal relationship between medical history and UC is difficult to prove because of the cross-sectional study design. Third, some patient selection bias cannot be completely avoided because control patients were recruited mainly from nephrology clinics while UC patients were recruited mostly during hospital admissions. Fourth, the number of patients with on-going UC in this study was relatively small. As this is an ongoing project, we will continue our recruiting program and further validate our UC biosignature in a larger cohort.

Conclusions

CA125 is a useful tumor marker for the diagnosis of UC in CKD patients but not HE4. A nomogram based on serum CA125 level, age, renal function, smoking, history of exposure to environmental carcinogens, use of NSAIDs and use of traditional Chinese medicine reveals a high accuracy for predicting UC in CKD patients.

References

1. Chung, C. L. et al. Sex differences in the development of malignancies among end-stage renal disease patients: a nationwide population-based follow-up study in Taiwan. *PLoS One* 7, e44675 (2012).
2. Ou, J. H. et al. Transitional cell carcinoma in dialysis patients. *Eur Urol* 37, 90–94 (2000).
3. Chiou, H. Y. et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. *American Journal of Epidemiology* 153, 411–418 (2001).
4. Wu, M. J. et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation* 43, 1091–1097 (2004).
5. Wang, Y. H. et al. Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. *J Hazard Mater* 262, 1139–1146 (2013).
6. Chung, C. I. et al. Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. *Toxicol Appl Pharmacol* **226**, 14–21 (2008).

7. Shinka, T. et al. Relationship between glutathione S-transferase M1 deficiency and urothelial cancer in dye workers exposed to aromatic amines. *J Urol* **159**, 380–383 (1998).

8. Steineck, G., Plato, N., Gerhardsson, M., Niorell, S. E. & Hogstedt, C. Increased risk of urothelial cancer in Stockholm during 1985-87 after exposure to benzene and exhausts. *Int J Cancer* **45**, 1012–1017 (1990).

9. Lai, M. N. et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. *Nephrology (Carlton)* **14**, 227–234 (2009).

10. Wang, S. M. et al. Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid. *PLoS One* **9**, e105218 (2014).

11. Cyne, M. Bladder cancer: aristolochic acid—one of the most potent carcinogens known to man. *Nat Rev Urol* **10**, 552 (2013).

12. Chen, C. H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. *Proc Natl Acad Sci USA* **109**, 8241–8246 (2012).

13. Chen, K. S., Lai, M. K., Huang, C. C., Chu, S. H. & Leu, M. L. Urolologic cancers in uremic patients. *American journal of kidney diseases: the official journal of the National Kidney Foundation* **25**, 694–700 (1995).

14. Lamm, S. H., Engel, A., Penn, C. A., Chen, R. & Feinleib, M. Arsenic cancer risk confounder in southwest Taiwan data set. *Environmental health perspectives* **114**, 1077–1082 (2006).

15. Yang, H. Y., Yang, J. D., Lo, T. C. & Chen, P. C. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. *J Urol* **189**, 48–52 (2013).

16. Messer, J. et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU Int* **108**, 701–705 (2011).

17. Lotan, Y. & Roehrborn, C. G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. *Urolgy* **61**, 109–118, discussion 118 (2003).

18. Ahmad, H., Djialadat, H., Cai, J., Miranda, G. & Daneshmand, S. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder. *Urol Oncol* **32**, 648–656 (2014).

19. Manvar, A. M., Wallen, E. M., Pruthi, R. S. & Nielsen, M. E. Prognostic value of CA 125 in transitional cell carcinoma of the bladder. *Exp Rev Anticancer Ther* **10**, 1877–1881 (2010).

20. Sangoi, A. R., Higgins, J. P., Rouse, R. V., Schneider, A. G. & McKenney, J. K. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact. *Mod Pathol* **22**, 660–667 (2009).

21. Koub, E. J., Lenz, A., Wallen, E. M. & Pruthi, R. S. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urol Oncol* **27**, 486–490 (2009).

22. Izes, J. K. et al. Ca 125 as a marker of tumor activity in advanced urothelial malignancy. *J Urol* **165**, 1908–1913 (2001).

23. Xi, Z., LinLin, M. & Ye, T. Human episipidosis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. *J Clin Lab Anal* **23**, 357–361 (2009).

24. Nagy, B. Jr. et al. Elevated human episipidosis protein 4 concentrations in chronic kidney disease. *Ann Clin Biochem* **49**, 377–380 (2012).

25. Camci, C. et al. The effect of continuous ambulatory peritoneal dialysis on serum CA-125 levels. *Eur J Gynaecol Oncol* **23**, 472–474 (2002).

26. Sevinc, A. et al. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. *Gynecol Oncol* **77**, 254–257 (2000).

27. Bastani, B. & Cha, N. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. *Am J Nephrol* **15**, 468–472 (1995).

28. Schmidt-Lucke, C. et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. *Circulation* **111**, 2981–2987 (2005).

29. Freiberg, M. S. et al. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. *Diabetes Care* **27**, 2954–2959 (2004).

30. Pesch, B. et al. Occupational risk factors for urothelial carcinoma: agent-specific results from a case-control study in Germany. *MURC Study Group. Multicenter Urothelial and Renal Cancer. Int J Epidemiol* **29**, 238–247 (2000).

31. Martin, D. E., Montgomery, E., Dobek, A. S., Patrissi, G. A. & Peura, D. A. Campylabacter pylor, NSAIDs, and smoking: risk factors for peptic ulcer disease. *Am J Gastroenterol* **84**, 1268–1272 (1989).

32. Zlotnik, A. & Abraira, V. A general-purpose nomogram generator for predictive logistic regression models. *Statistical Journal* **15**, 537–546 (2015).

33. Lowrance, W. T., Ordonez, J., Udalitsova, N., Russo, P. & Go, A. S. CKD and the risk of incident cancer. *J Am Soc Nephrol* **25**, 2327–2334 (2014).

34. Chen, C. Y., Liao, Y. M., Tsai, W. M. & Kuo, H. C. Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. *J Formos Med Assoc* **106**, 992–998 (2007).

35. Xiong, G. et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. *J Formos Med Assoc* **113**, 521–526 (2014).

36. Heney, N. M., Nocks, B. N., Daly, J. J., Blitzer, P. H. & Parkhurst, E. C. Prognostic factors in carcinoma of the ureter. *J Urol* **125**, 632–636 (1981).

37. Stewart, J. H. et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. *J Am Soc Nephrol* **14**, 197–207 (2003).

38. Zhou, L. et al. Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China. *Clin Med J (Engl)* **125**, 4460–4465 (2012).

39. Arlt, V. M. et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. *Int J Cancer* **111**, 977–980 (2004).

40. Arlt, V. M., Stiborova, M. & Schmeiser, H. H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. *Mutagenesis* **17**, 265–277 (2002).

41. Poon, S. L. et al. Mutation signatures implicate aristolochic acid in bladder cancer development. *Genome Med* **7**, 38 (2015).

Acknowledgements

This study is mainly supported by grants from Academia Sinica, Taiwan (Grant Number BI 10150264, BM102021124, BM103010089 and BM104010113) and partially supported by the Taiwan Department of Health Cancer Research Center of Excellence (Grant Number DOH101-TD-C-111-005). In addition, we would like to thank all nephrologists and urologists who helped to enroll the patients. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
C.Y. design and draft the article, K.H. the conception and design of the study, H.C. critical revision of the article, M.C. interpretation of the data and critical revision, C.C. analysis and interpretation of the data, C.C. the conception and design of the study, B.G. and T.W. acquisition and analysis of the data, C.C. final approval, C.L. critical revision of the article.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019